Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib and Belatacept for Antibody-Mediated Rejection in Kidney Transplant
NCT06918990Phase 1Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2026
- Primary completion
- Jun 2027
- Modality
- Reversible Covalent Inhibitors, Irreversible Covalent Inhibitors, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of carfilzomib and belatacept in kidney transplant rejection, sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Proportion of subjects who do not meet a stopping rule for safety at 12 months. Started May 2026; status: recruiting.
02
Drugs
carfilzomibbelatacept
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT06918990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06918990.